Please use this identifier to cite or link to this item: 10.1080/14760584.2019.1573145
Title: Burden of varicella in Central and Eastern Europe : findings from a systematic literature review
Authors: Mészner, Zsófia
Wysocki, Jacek
Richter, Darko
Zavadska, Dace
Ivaskeviciene, Inga
Usonis, Vytautas
Pokorn, Marko
Mangarov, Atanas
Jancoriene, Ligita
Man, Sorin C.
Kristufkova, Zuzana
Jesenak, Milos
Tešović, Goran
Pluta, Justyna
Wolfson, Lara J.
Department of Paediatrics
Keywords: Burden of illness;Central and Eastern Europe;systematic literature review;vaccination;varicella;3.1 Basic medicine;1.1. Scientific article indexed in Web of Science and/or Scopus database;Immunology;Molecular Medicine;Pharmacology;Drug Discovery;SDG 3 - Good Health and Well-being
Issue Date: 4-Mar-2019
Citation: Mészner , Z , Wysocki , J , Richter , D , Zavadska , D , Ivaskeviciene , I , Usonis , V , Pokorn , M , Mangarov , A , Jancoriene , L , Man , S C , Kristufkova , Z , Jesenak , M , Tešović , G , Pluta , J & Wolfson , L J 2019 , ' Burden of varicella in Central and Eastern Europe : findings from a systematic literature review ' , Expert Review of Vaccines , vol. 18 , no. 3 , pp. 281-293 . https://doi.org/10.1080/14760584.2019.1573145
Abstract: Introduction: Vaccination against varicella rapidly reduces disease incidence, resulting in reductions in both individual burden and societal costs. Despite these benefits, there is no standardization of varicella immunization policies in Europe, including countries in Central and Eastern Europe (CEE). Areas covered: This systematic literature review identified publications on the epidemiology of varicella, its associated health and economic burden, and vaccination strategies within the CEE region, defined as Albania, Bosnia-Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Serbia, Slovakia, and Slovenia. Twenty-six studies were identified from a search of PubMed, Embase®, and MEDLINE® biomedical literature databases, supplemented by gray literature and country-specific/global websites. Expert commentary: Limited information exists in published studies on the burden of varicella in CEE. The wide variability in incidence rates between countries is likely explained by a lack of consistency in reporting systems. Funded universal varicella vaccination (UVV) in CEE is currently available only in Latvia as a one-dose schedule, but Hungary together with Latvia are introducing a two-dose strategy in 2019. For countries that do not provide UVV, introduction of vaccination is predicted to provide substantial reductions in cases and rates of associated complications, with important economic benefits.
Description: Funding Information: The authors take full responsibility for the scope, direction, and content of the manuscript, and have approved the submitted manuscript. Medical writing assistance was provided by Eleanor Finn of PAREXEL International and was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. The authors wish to thank the following for contributions in development of the manuscript: Barbara J. Kuter, PhD, MPH, Global Vaccines Medical Affairs, and Tracey J. Weiss, Center for Observational and Real-World Evidence (CORE), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Funding Information: The study was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Funding Information: J. Wysocki received travel grants to attend international scientific conferences and fees for lectures from Pfizer and payment from a grant sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. I. Ivaskeviciene has received a USA travel grant to attend international scientific meeting, from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth. M. Pokorn has received a research grant from Pfizer and payment for lectures from Pfizer, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and GSK. L. Jancoriene has received travel grants to attend international scientific conferences and fees for lectures from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, AbbVie and Pfizer and payment for a clinical study sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. J. Pluta and L.J. Wolfson are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and stockholders of Merck & Co., Inc., Kenilworth, NJ, USA. Publisher Copyright: © 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
DOI: 10.1080/14760584.2019.1573145
ISSN: 1476-0584
Appears in Collections:Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure

Files in This Item:


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.